증후군 멀티플렉스 진단 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 유형별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Syndromic Multiplex Diagnostics Market Growth & Trends:

The global syndromic multiplex diagnostics market size is anticipated to reach USD 3.66 billion by 2030, and it is expected to expand at a CAGR of 3.91% from 2025 - 2030, according to a new report by Grand View Research, Inc. The market's growth is attributed to factors such as technological advancements in diagnostics technologies, rising prevalence various diseases, growing demand for rapid and accurate diagnostics solutions, and global aging population.

Traditional diagnostic tests often require multiple steps and take longer to deliver results, whereas syndromic multiplex diagnostics offer a comprehensive solution by testing for multiple pathogens simultaneously in a single sample. This capability significantly reduces the time for diagnosis, increasing their demand in various healthcare settings where rapid diagnostics are preferred. Moreover, the high prevalence of various conditions, such as respiratory diseases, gastrointestinal conditions, and others, requiring effective diagnostics solutions further contributes to the market growth. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2023, more than 2.4 million instances of syphilis, gonorrhea, and chlamydia were diagnosed and documented in the U.S. This total includes over 209,000 syphilis cases, over 600,000 gonorrhea cases, and more than 1.6 million chlamydia cases. This high prevalence of infectious diseases is expected to fuel the market growth over the forecast period.

Moreover, the increasing R&D efforts by market players are leading to the development of new diagnostics solutions, increasing the availability of multiple diagnostics products for the end users. For instance, in January 2021, Singapore launched the Fortitude SARS-CoV-2 & Flu A/B Test, a multiplex diagnostic kit developed by MiRXES. This test detects and differentiates SARS-CoV-2 and influenza A/B, providing more accurate diagnoses. The kit received Provisional Authorisation from Singapore's Health Sciences Authority (HSA). The development of such effective solutions offering better results is expected to increase the adoption of these solutions and drive market growth.

The growing demand for Point-of-Care Testing (POCT) also contributes to market growth. With the rise in the demand for rapid diagnosis, especially in remote or underserved regions, multiplex diagnostic systems offer significant advantages by allowing for the simultaneous detection of multiple pathogens or diseases with a single test. Additionally, focuses on improving the healthcare infrastructure in regions such as Asia, Latin America and MEA are encouraging the implementation of integrated diagnostic systems that can provide faster and more accurate results.

Syndromic Multiplex Diagnostics Market Report Highlights:

• Based on type, the bipolar respiratory segment held the largest market share in 2024. This is attributed to the rising prevalence of various respiratory infections and rising availability of effective diagnostics technologies.
• Based on end use, the diagnostics laboratories segment held the largest market share in 2024. This is attributed to the high patient footfall in these facilities and their better accessibility to patients.
• Based on region, North America dominated the market and accounted for a 41.85% share in 2024. The syndromic multiplex diagnostics industry in North America is experiencing significant growth driven by the presence of key market players, evolving regulatory landscape, developed healthcare infrastructure, and increasing prevalence of various infectious diseases.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. End Use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. End Use outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Syndromic Multiplex Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of infectious diseases
    • 3.2.1.2. Advancements in diagnostics technologies
    • 3.2.1.3. Growing demand for effective diagnostics solutions
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of syndromic diagnostics solutions
• 3.3. Syndromic Multiplex Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Syndromic Multiplex Diagnostics Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Syndromic Multiplex Diagnostics Market: Type Movement Analysis
• 4.3. Syndromic Multiplex Diagnostics Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 4.4. Respiratory
  • 4.4.1. Respiratory Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Gastrointestinal
  • 4.5.1. Gastrointestinal Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Central Nervous System
  • 4.6.1. Central Nervous System Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Other Types of Syndromes (cUTI and STDs)
  • 4.7.1. Other Types of Syndromes (cUTI and STDs) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Syndromic Multiplex Diagnostics Market: End Use Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Syndromic Multiplex Diagnostics Market: End Use Movement Analysis
• 5.3. Syndromic Multiplex Diagnostics Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 5.4. Hospitals
  • 5.4.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Diagnostic Laboratories
  • 5.5.1. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Others
  • 5.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Syndromic Multiplex Diagnostics Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2023 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Global Regional Market Snapshot
• 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.5. North America
  • 6.5.1. U.S.
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/Reimbursement
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Canada
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/Reimbursement
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. Mexico
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/Reimbursement
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Europe
  • 6.6.1. UK
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/Reimbursement
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Germany
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/Reimbursement
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.3. France
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/Reimbursement
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.4. Italy
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework/Reimbursement
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.5. Spain
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework/Reimbursement
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.6. Norway
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework/Reimbursement
    • 6.6.6.3. Competitive scenario
    • 6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.7. Sweden
    • 6.6.7.1. Key country dynamics
    • 6.6.7.2. Regulatory framework/Reimbursement
    • 6.6.7.3. Competitive scenario
    • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.8. Denmark
    • 6.6.8.1. Key country dynamics
    • 6.6.8.2. Regulatory framework/Reimbursement
    • 6.6.8.3. Competitive scenario
    • 6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Asia Pacific
  • 6.7.1. Japan
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/Reimbursement
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. China
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/Reimbursement
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. India
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/Reimbursement
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Australia
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/Reimbursement
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.5. South Korea
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Regulatory framework/Reimbursement
    • 6.7.5.3. Competitive scenario
    • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.6. Thailand
    • 6.7.6.1. Key country dynamics
    • 6.7.6.2. Regulatory framework/Reimbursement
    • 6.7.6.3. Competitive scenario
    • 6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Latin America
  • 6.8.1. Brazil
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory framework/Reimbursement
    • 6.8.1.3. Competitive scenario
    • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.2. Argentina
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework/Reimbursement
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. MEA
  • 6.9.1. South Africa
    • 6.9.1.1. Key country dynamics
    • 6.9.1.2. Regulatory framework/Reimbursement
    • 6.9.1.3. Competitive scenario
    • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.2. Saudi Arabia
    • 6.9.2.1. Key country dynamics
    • 6.9.2.2. Regulatory framework/Reimbursement
    • 6.9.2.3. Competitive scenario
    • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.3. UAE
    • 6.9.3.1. Key country dynamics
    • 6.9.3.2. Regulatory framework/Reimbursement
    • 6.9.3.3. Competitive scenario
    • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.4. Kuwait
    • 6.9.4.1. Key country dynamics
    • 6.9.4.2. Regulatory framework
    • 6.9.4.3. Competitive scenario
    • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2023
  • 7.3.4. Abbott Laboratories
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Services benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Thermo Fisher Scientific, Inc.
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Services benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. F. Hoffmann-La Roche Ltd
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Services benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Qiagen
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Services benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. bioMerieux
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Services benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. DiaSorin S.p.A (Luminex Corporation)
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Services benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Hologic, Inc.
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Services benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. Becton, Dickinson and Company (BD)
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Services benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. Applied BioCode
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Services benchmarking
    • 7.3.12.4. Strategic initiatives
  • 7.3.13. QIAGEN
    • 7.3.13.1. Company overview
    • 7.3.13.2. Financial performance
    • 7.3.13.3. Services benchmarking
    • 7.3.13.4. Strategic initiatives
  • 7.3.14. Curetis GmbH
    • 7.3.14.1. Company overview
    • 7.3.14.2. Financial performance
    • 7.3.14.3. Services benchmarking
    • 7.3.14.4. Strategic initiatives